Global Leading Market Research Publisher QYResearch announces the release of its latest report “Oligonucleotide Contract Manufacturing Service – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Oligonucleotide Contract Manufacturing Service market, including market size, share, demand, industry development status, and forecasts for the next few years.
For biopharmaceutical companies, gene therapy developers, and emerging RNA therapeutics pioneers, the transition from research-scale oligonucleotide synthesis to commercial manufacturing represents one of the most significant bottlenecks in drug development. Oligonucleotides—short strands of DNA and RNA—are the foundation of breakthrough therapeutic modalities including antisense oligonucleotides (ASOs), small interfering RNA (siRNA), CRISPR guide RNAs, and mRNA vaccines. However, the complex chemistry, stringent purity requirements, and regulatory demands of GMP-grade oligonucleotide production require specialized expertise and capital-intensive infrastructure. Oligonucleotide contract manufacturing services (CDMOs) fill this critical gap, providing end-to-end capabilities from custom synthesis and purification to process scale-up and regulatory support. As the pipeline of oligonucleotide-based therapeutics continues to expand—with over 50 approved products and hundreds in clinical development—the demand for reliable, high-quality contract manufacturing is accelerating dramatically. This report delivers comprehensive market intelligence for stakeholders navigating this rapidly expanding segment of the biopharmaceutical CDMO industry.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6085602/oligonucleotide-contract-manufacturing-service
Market Scale and Growth Trajectory
The global market for Oligonucleotide Contract Manufacturing Service was estimated to be worth US$ 1996 million in 2025 and is projected to reach US$ 4154 million, growing at a CAGR of 11.2% from 2026 to 2032. This exceptional growth reflects the convergence of several powerful drivers: the expanding pipeline of oligonucleotide-based therapeutics across RNA interference, antisense, and gene editing modalities; the increasing number of approved oligonucleotide drugs transitioning to commercial-scale production; the growing preference for outsourcing complex manufacturing to specialized CDMOs; and the continuous advancement in synthesis and purification technologies that improve yield and reduce costs. According to QYResearch data, the market’s explosive growth trajectory is further supported by the expansion of CRISPR-based therapeutics, the resurgence of mRNA platforms post-pandemic, and the increasing regulatory acceptance of oligonucleotide modalities.
Key Market Trends Driving Growth:
- RNA Therapeutics Expansion: ASOs, siRNA, and mRNA platforms drive demand for GMP-grade oligonucleotides
- Gene Editing Pipeline: CRISPR-based therapies require high-quality guide RNAs (gRNAs)
- Outsourcing Trend: Biopharma companies increasingly rely on CDMOs for complex oligonucleotide manufacturing
- Commercial Approvals: Growing number of approved oligonucleotide drugs require commercial-scale production
- Technology Advancements: Improved synthesis, purification, and analytical methods enable higher yields and quality
Understanding Oligonucleotide Contract Manufacturing Services: Capabilities, Technologies, and Applications
Oligonucleotide Contract Manufacturing provides end-to-end services for the production of synthetic oligonucleotides—short strands of nucleic acids used in research, diagnostics, and increasingly, therapeutic applications. These services encompass custom synthesis of various types of oligonucleotides (e.g., antisense oligonucleotides [ASOs], small interfering RNA [siRNA], guide RNAs [gRNAs] for CRISPR applications, mRNA fragments), downstream modifications (e.g., conjugation, labeling, phosphorothioate backbones), purification, quality control (including analytical characterization), process development, scale-up, and regulatory support for Good Manufacturing Practice (GMP) compliance.
Key Capabilities:
- Custom Synthesis: Production of diverse oligonucleotide types with varying lengths, sequences, and chemical modifications
- Downstream Modifications: Conjugation with lipids, peptides, and other moieties for enhanced delivery; labeling for detection; backbone modifications for stability
- Purification: High-performance liquid chromatography (HPLC), ion exchange, and other methods achieving >90-99% purity
- Analytical Characterization: Mass spectrometry, HPLC, and other methods ensuring identity, purity, and potency
- Process Development: Optimization of synthesis, purification, and formulation for specific applications
- Scale-Up: Transition from research-scale (mg) to commercial-scale (kg) manufacturing
- GMP Compliance: Regulatory support for investigational and commercial products
Key Oligonucleotide Types:
- DNA Oligonucleotides: Including antisense oligonucleotides (ASOs), aptamers, primers, probes, and guide RNAs for CRISPR applications
- RNA Oligonucleotides: Including small interfering RNA (siRNA), microRNA (miRNA), mRNA fragments, and RNA-based therapeutics
Key Applications:
- Pharmaceuticals: The largest and fastest-growing segment, encompassing ASOs for rare diseases, siRNA for metabolic and genetic disorders, CRISPR-based therapies, and mRNA vaccines and therapeutics
- Diagnostics: Including oligonucleotide-based diagnostic assays, companion diagnostics, and research tools
- Others: Including agricultural biotechnology, industrial applications, and research reagents
Industry Development Characteristics: Market Segmentation and Competitive Landscape
Market Segmentation by Oligonucleotide Type
- RNA Oligonucleotides: The fastest-growing segment, driven by the expansion of siRNA therapeutics, mRNA platforms, and CRISPR applications
- DNA Oligonucleotides: The largest segment, including ASOs, aptamers, and guide RNAs
Competitive Landscape
The oligonucleotide contract manufacturing market features established CDMOs, specialized oligonucleotide manufacturers, and integrated life science suppliers:
- Global CDMOs and Specialists: Lonza, Bachem, WuXi STA, Nitto Denko Avecia Inc, Eurogentec S.A., TriLink BioTechnologies, BBI Life Sciences, GeneDesign, Creative Biogene, General Biosystems
- Integrated Life Science Suppliers: Integrated DNA Technologies (IDT), Agilent, Eurofins Genomics, Merck, L.G.C Biosearch Technologies, GenScript, QIAGEN, LC Sciences, Twist Bioscience
Industry Trends: The RNA Therapeutics Revolution
Commercial Pipeline Expansion
A defining characteristic of current market development is the exponential growth of the oligonucleotide therapeutics pipeline. According to industry data:
- Approved Products: Over 15 oligonucleotide-based drugs approved globally (ASOs, siRNA, aptamers)
- Clinical Pipeline: Over 100 oligonucleotide candidates in clinical development
- Emerging Modalities: CRISPR-based therapies, mRNA therapeutics, and next-generation RNAi platforms
Each approved product requires commercial-scale manufacturing capacity, driving sustained demand for CDMO services.
A recent case study from a leading oligonucleotide CDMO illustrates the scale of commercial manufacturing requirements. The CDMO partnered with a biopharmaceutical company to manufacture a commercial ASO product for a rare genetic disorder. The project involved:
- Scale: Kilogram-scale synthesis of complex oligonucleotide with multiple chemical modifications
- Purification: Multi-step purification achieving >99% purity
- Analytics: Comprehensive characterization supporting regulatory submission
- GMP Compliance: Successful FDA inspection with no observations
- Capacity: Ongoing commercial supply supporting global patient population
CRISPR Guide RNA Manufacturing
CRISPR-based therapies require high-quality, GMP-grade guide RNAs (gRNAs) as critical components of the therapeutic product. The unique requirements for CRISPR gRNAs—including the need for co-delivery with Cas proteins or mRNA—create specialized manufacturing needs that CDMOs are well-positioned to address.
Exclusive Analyst Observation: The Capacity Crunch
Our ongoing market monitoring reveals that the oligonucleotide manufacturing industry is experiencing a significant capacity crunch. With the rapid expansion of the clinical pipeline and multiple commercial approvals, CDMOs are investing heavily in capacity expansion:
- New Facilities: Major CDMOs announcing dedicated oligonucleotide manufacturing facilities
- Scale-Up: Transition from gram to kilogram-scale synthesis
- Technology Investment: Continuous flow synthesis, improved purification, and automation
- Regional Expansion: Capacity expansion in Asia, North America, and Europe
For biopharmaceutical companies, securing manufacturing capacity with experienced CDMOs is becoming a strategic imperative.
Technical Challenges and Policy Drivers
Technical Hurdles: Despite significant advances, oligonucleotide manufacturing faces several challenges:
- Synthesis Complexity: Long oligonucleotides and complex chemical modifications require specialized expertise
- Purification Demands: Achieving >99% purity for therapeutic applications is technically demanding
- Analytical Characterization: Comprehensive characterization for regulatory submission requires sophisticated analytics
- Scale-Up: Transitioning from research to commercial scale while maintaining quality
Regulatory Landscape: Oligonucleotide therapeutics are regulated as drug substances with specific CMC requirements. Regulatory expectations for oligonucleotide manufacturing include:
- Process Validation: Validated synthesis, purification, and formulation processes
- Characterization: Comprehensive structural and purity characterization
- Impurity Control: Control of process-related and product-related impurities
- Stability: Demonstrated stability under storage and handling conditions
Strategic Implications for Industry Participants
For biopharmaceutical companies, CDMOs, and life science investors, several considerations emerge from current market dynamics:
Early CDMO Engagement: For oligonucleotide therapeutics, engaging a CDMO early in development enables process optimization and seamless scale-up to commercial supply.
Capacity Planning: With increasing demand and capacity constraints, securing manufacturing capacity with experienced CDMOs is essential for product launch and commercial supply.
Technology Differentiation: CDMOs with advanced capabilities—including novel synthesis technologies, high-resolution purification, and robust analytical methods—capture premium market positions.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
